



Financial Tear Sheet

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva's lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ...

Share Performance

Last	Change (%)	Volume	Open
9.79 USD	▼ -0.02 -(0.20%)	11,250	9.91

Recent News

06/26/17

[Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board](#)

06/26/17

[Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding Common Shares of Nabriva Therapeutics AG and Outstanding American Depositary Shares of Nabriva Therapeutics AG](#)

06/05/17

[Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/19/17	4

Management

Colin Broom	Chief Executive Officer
Robert Crotty	General Counsel

06/19/17	8-K	Steven Gelone	Chief Development Officer
06/16/17	3	Elyse Seltzer	Chief Medical Officer
06/09/17	425	Gary Sender	Chief Financial Officer
		David Garrett	Vice President, Corporate Controller and Head of Investor Relations
		Werner Heilmayer	Vice President Research, CMC & IP
		Ernie Kelly	Vice President Quality
		Thomas Lembck	Chief Information Officer
		William Sargent	Vice President Commercial Strategy and Investor Relations

Data provided by Nasdaq. Minimum 15 minutes delayed.